Expert Ratings For Intellia Therapeutics
Expert Ratings For Intellia Therapeutics
Intellia Therapeutics的專家評級
In the last three months, 7 analysts have published ratings on Intellia Therapeutics (NASDAQ:NTLA), offering a diverse range of perspectives from bullish to bearish.
在過去的三個月中，有7位分析師公佈了對Intellia Therapeutics（納斯達克股票代碼：NTLA）的評級，提供了從看漲到看跌的不同視角。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have recently evaluated Intellia Therapeutics and provided 12-month price targets. The average target is $71.0, accompanied by a high estimate of $120.00 and a low estimate of $54.00. A 2.35% drop is evident in the current average compared to the previous average price target of $72.71.
分析師最近對Intellia Therapeutics進行了評估，並提供了12個月的目標股價。平均目標爲71.0美元，最高估計值爲120.00美元，低估值爲54.00美元。與之前的平均目標股價72.71美元相比，目前的平均價格下降了2.35％。
Understanding Analyst Ratings: A Comprehensive Breakdown
了解分析師評級：全面細分
A clear picture of Intellia Therapeutics...
通過對分析師...
登入免費觀看全文
登入/註冊